General Commentary ARTICLE
Erratum: The promise of neuroprotective agents in Parkinson's disease
- 1The Department of Biological Sciences, DePaul University, Chicago, IL, USA
- 2The Cellular and Molecular Pharmacology Department, The Chicago Medical School, RFUMS, North Chicago, IL, USA
A commentary on
The promise of neuroprotective agents in Parkinson's disease
by Seidl, S. E., and Potashkin, J. A., (2011). Front. Neurol. 2:68. doi: 10.3389/fneur.2011.00068
After our article was published online, it was brought to our attention that in Table 1 we incorrectly stated the findings from a study testing the safety of Isradipine (Simuni et al., 2010). We have thus changed the text in the table to reflect the results that Isradipine has been shown to be safe and well-tolerated in PD patients.
Citation: Seidl SE and Potashkin JA (2013) Erratum: The promise of neuroprotective agents in Parkinson's disease. Front. Neurosci. 7:69. doi: 10.3389/fnins. 2013.00069
Received: 27 March 2013; Accepted: 15 April 2013;
Published online: 01 May 2013.
Edited by:Nick Andrews, Children's Hospital Boston, USA
Copyright © 2013 Seidl and Potashkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.